Peijia medical-b (09996) announced that on May 20, 2022, the group received the approval of the State Drug Administration for the registration application of Tethys as thrombus suction catheter, making it the 12th Neurointerventional product approved by the State Drug Administration.
It is reported that Tethys as thrombus suction catheter is an acute ischemic stroke product with large lumen, high in place and suction indications developed by Jiaqi biology Co., Ltd. (Jiaqi biology, a wholly-owned subsidiary of the company). The 0.071 inch lumen of Tethys as thrombus suction catheter can improve the thrombus suction ability and shorten the operation time. The product has a longer distal soft segment, which can comply with tortuous blood vessels and improve the positioning of distal blood vessels. The optimized transition section design improves the tracking performance and is easy to push to the target vessel. The product adopts the whole process “coil + braid” composite structure, with strong negative pressure resistance and good lumen retention ability. Tethys as thrombus suction catheter provides 2 inner diameters and 4 effective lengths, a total of 14 models. The operator can choose according to the operation habits and patient conditions to meet different clinical needs.
According to a number of high-quality clinical studies, thrombus aspiration has become the first-line treatment of intravascular interventional therapy in patients with acute ischemic stroke. So far, for patients with acute ischemic stroke, Jiaqi biology has been able to provide a variety of treatment schemes including stent thrombectomy and suction thrombectomy. The product series includes Tethys as thrombus suction catheter, syphonet thrombectomy stent, Tethys intermediate guide catheter, presgo micro guide wire, presgo micro guide tube and fluxcap balloon guide tube to be approved, so as to meet the clinical needs of mechanical thrombectomy.
In addition, Jiaqi biology will continue to enrich the product layout in the field of ischemic stroke, continue to help the construction of China stroke center and promote the treatment of patients with acute ischemic stroke.
